Results 251 to 260 of about 231,925 (363)

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami   +10 more
wiley   +1 more source

Podocyte Glucocorticoid Receptor Expression and Treatment Outcome in Idiopathic Nephrotic Syndrome. [PDF]

open access: yesKidney Int Rep
van den Berge BT   +4 more
europepmc   +1 more source

Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin   +15 more
wiley   +1 more source

Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan   +8 more
wiley   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich   +10 more
wiley   +1 more source

Glucocorticoid Receptor and SUMO Fluctuations in Response to Pulsatile Glucocorticoids In Vitro and in Male Rat Brains.

open access: yesEndocrinology
Rivers CA   +6 more
europepmc   +1 more source

Effects of glucocorticoid receptor activation on gene expression and antiviral responses in Atlantic salmon (Salmo salar L.) red blood cells. [PDF]

open access: yesVet Res
Tsoulia T   +10 more
europepmc   +1 more source

Deciphering the catalytic and pharmacological mechanisms of Coptis chinensis herbzymes to renovate intestinal microenvironment for colitis alleviation

open access: yesBMEMat, EarlyView.
The synthesized CCzymes possess both antioxidant enzyme activity and pharmacological properties inherent to Coptis chinensis. By their antioxidant enzyme activity, CCzymes can attenuate oxidative stress within the inflammatory region of ulcerative colitis (UC), while their pharmacological activity acts on macrophage polarization and the intestinal ...
Zhichao Deng   +10 more
wiley   +1 more source

SIRT2 attenuates stress-induced skeletal muscle atrophy by inhibiting glucocorticoid receptor signalling

open access: yes
Tamta AK   +28 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy